IHS Chemical Week

Markets :: Fine Chemicals/Biotech :: Pharmaceutical ingredients

Sorrento to acquire antibody-drug conjugation technology

5:22 AM MST | November 14, 2013 | Deepti Ramesh

Sorrento Therapeutics (San Diego), a publicly traded, development-stage biopharmaceutical company, says it has entered into a definitive agreement to acquire Concortis Biosystems (San Diego) in a deal that provides Sorrento with a comprehensive technology platform for generation of antibody-drug conjugates (ADCs). Sorrento, under the terms of the agreement, will issue an aggregate of 1,331,978 shares of its common stock to the Concortis shareholders. This acquisition will enable Sorrento to utilize the antibodies identified from its G-MAB library along with...

This information is only available to Chemical Week subscribers.


Forgot your user ID or password?
Click here to have it sent to you.

Not an IHS Chemical Week subscriber yet?

Here's why you should be:

  • 31 issues of Chemical Week magazine a year in print or digital format
  • Real time news and analysis on chemweek.com 
  • 20+ years of online archives
  • Topical e-newsletters that capture the most impactful events
  • Special issues with a regional or company focus
  • Global Outlook issue

Subscribe now


contact us | about us | privacy policy | sitemap

ihsCopyright © IHS, Inc.All rights reserved.Reproduction in whole or in part without permission is prohibited.

North Asia Russia Southeast Asia China India/Pakistan Middle East Eastern Europe Western Europe Central America Canada USA Australia/New Zealand South America Africa